Zacks: Brokerages Anticipate Trillium Therapeutics Inc (TRIL) Will Announce Earnings of -$0.67 Per Share

Equities analysts expect Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) to post earnings of ($0.67) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Trillium Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.78) and the highest estimate coming in at ($0.55). Trillium Therapeutics posted earnings of ($0.84) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 20.2%. The firm is expected to issue its next earnings report on Friday, November 9th.

According to Zacks, analysts expect that Trillium Therapeutics will report full year earnings of ($2.49) per share for the current financial year, with EPS estimates ranging from ($2.60) to ($2.34). For the next year, analysts expect that the company will post earnings of ($2.20) per share, with EPS estimates ranging from ($2.53) to ($1.79). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Trillium Therapeutics.

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last posted its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.05).

Several equities research analysts have recently weighed in on the company. Zacks Investment Research downgraded Trillium Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 26th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Trillium Therapeutics in a report on Monday, August 13th.

Several hedge funds and other institutional investors have recently modified their holdings of TRIL. Stanley Laman Group Ltd. raised its holdings in shares of Trillium Therapeutics by 26.7% in the second quarter. Stanley Laman Group Ltd. now owns 137,091 shares of the biotechnology company’s stock worth $823,000 after buying an additional 28,907 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Trillium Therapeutics by 245.3% in the second quarter. Renaissance Technologies LLC now owns 144,000 shares of the biotechnology company’s stock worth $864,000 after buying an additional 102,300 shares during the period. Baker BROS. Advisors LP raised its holdings in shares of Trillium Therapeutics by 25.0% in the second quarter. Baker BROS. Advisors LP now owns 511,763 shares of the biotechnology company’s stock worth $3,071,000 after buying an additional 102,440 shares during the period. Finally, Wealth Alliance Advisory Group LLC purchased a new stake in shares of Trillium Therapeutics in the third quarter worth approximately $126,000. Hedge funds and other institutional investors own 48.77% of the company’s stock.

NASDAQ:TRIL opened at $3.34 on Friday. The company has a market capitalization of $47.01 million, a PE ratio of -0.94 and a beta of 2.40. Trillium Therapeutics has a 1 year low of $2.83 and a 1 year high of $13.30.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

Featured Story: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on Trillium Therapeutics (TRIL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply